Shionogi & Co., Ltd. (SGIOY)

Market Cap	15.23B
Revenue (ttm)	3.05B
Net Income (ttm)	1.24B
Shares Out	n/a
EPS (ttm)	1.46
PE Ratio	12.27
Forward PE	n/a
Dividend	0.44 (5.01%)
Ex-Dividend Date	Sep 29, 2025

Volume	3,150
Average Volume	112,147
Open	8.88
Previous Close	8.87
Day's Range	8.83 - 8.88
52-Week Range	6.53 - 8.99
Beta	0.12
RSI	59.72
Earnings Date	Jul 28, 2025

About Arcadium Lithium

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1878
• Employees: 4,955
• Stock Exchange: OTCMKTS
• Ticker Symbol: SGIOY

Financial Performance

In 2024, Shionogi &'s revenue was 438.27 billion, an increase of 0.73% compared to the previous year's 435.08 billion. Earnings were 170.44 billion, an increase of 5.19%.